发明名称 |
INTERFERON EPSILON (IFNE1) AS A MARKER FOR TARGETED CANCER THERAPY |
摘要 |
<p>The present invention relates to a method employing Interferon Epsilon (IFNE1) as a therapeutic response, prognostic, or pharmacodynamic marker for cancer chemotherapeutic treatment involving the use of cyclin dependent kinase (CDK) inhibitors. The inventors have identified IFNE1 as a biomarker transcript that is upregulated when cancer cells are treated with CDK inhibitors. In an embodiment, the method of the invention includes measuring a level of IFNE1 mRNA or IFNE1 protein in a subject's tumor, blood or other tissue. An increase in the level of IFNE1 compared to control level can indicate that the CDK inhibitor has produced a therapeutic response or can determine whether a tumor is sensitive to a CDK inhibitor.</p> |
申请公布号 |
EP2307561(A2) |
申请公布日期 |
2011.04.13 |
申请号 |
EP20080763271 |
申请日期 |
2008.06.10 |
申请人 |
PIRAMAL LIFE SCIENCES LIMITED |
发明人 |
SHANKAR, SUNITA;VED, URVI;SHARMA, SOMESH |
分类号 |
C12Q1/68;G01N33/53;G01N33/574 |
主分类号 |
C12Q1/68 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|